Neurological Disorder Diagnostics Market Report 2026

Neurological Disorder Diagnostics Market Overview

• Neurological Disorder Diagnostics market size has reached to $12.61 billion in 2025 • Expected to grow to $17.75 billion in 2030 at a compound annual growth rate (CAGR) of 7% • Growth Driver: Rising Alzheimer's Prevalence Fuels Growth in Neurological Disorder Diagnostics Market • Market Trend: Innovative Neurological Disease Quantification Software Transforming Diagnostics Worldwide • North America was the largest region in 2025.

What Is Covered Under Neurological Disorder Diagnostics Market?

Neurological disorder diagnostics refer to the various methods and technologies used to identify, assess, and monitor diseases affecting the nervous system, including the brain, spinal cord, and nerves. These diagnostics involve advanced imaging techniques, biomarker analysis, genetic testing, and cognitive assessments to detect abnormalities, determine disease presence and progression, and guide treatment strategies for neurological conditions. The main components in the neurological disorder diagnostics market are instruments, reagents, kits, software, and services. Instruments refer to the physical devices used in diagnosing neurological disorders. The various technologies include immunoassay and polymerase chain reaction (PCR) techniques, and several types of diseases including Alzheimer’s disease, dementia, Parkinson’s disease, epilepsy, traumatic brain injury, and others. The different end users encompass hospitals and clinics, diagnostic centers, and academic and research institutes.

What Is The Neurological Disorder Diagnostics Market Growth Forecast?

The neurological disorder diagnostics market size is expected to see strong growth in the next few years. It will grow to $17.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to increasing adoption of precision neurology approaches, rising investments in digital diagnostics platforms, expansion of personalized treatment planning, growing use of tele-neurology services, advancements in neuroinformatics and analytics. Major trends in the forecast period include increasing adoption of AI-assisted neuroimaging tools, rising use of biomarker-based diagnostic kits, growing integration of genetic and molecular testing, expansion of remote and digital cognitive assessments, enhanced focus on early disease detection.

Global Neurological Disorder Diagnostics Market Segmentation

1) By Component: Instruments, Reagents, Kits, Software, Services 2) By Technology: Immunoassay, Polymerase Chain Reaction (PCR) Techniques 3) By Disease Type: Alzheimer's Disease, Dementia, Parkinson's Disease, Epilepsy, Traumatic Brain Injury, Other Disease Types 4) By End User: Hospitals And Clinics, Diagnostic Centers, Academic And Research Institutes Subsegments: 1) By Instruments: Electroencephalography (EEG) Machines, Magnetic Resonance Imaging (MRI) Machines, Computed Tomography (CT) Scanners, Positron Emission Tomography (PET) Scanners, Lumbar Puncture Equipment, Ultrasound Devices, Neurostimulation Devices, Transcranial Magnetic Stimulation (TMS) Devices, 2) By Reagents: Biochemical Reagents, Antibodies, DNA Probes, RNA Probes, Enzyme-linked Immunosorbent Assay (ELISA) Reagents, Polymerase Chain Reaction (PCR) Reagents, Sample Collection Reagents 3) By Kits: Diagnostic Test Kits, Genetic Testing Kits, Biomarker Detection Kits, Immunoassay Kits, Point-of-Care Testing Kits, Screening Kits for Neurological Disorders 4) By Software: Diagnostic Software for Imaging Analysis, Data Management Software, Clinical Decision Support Software, Patient Management Software, Laboratory Information Management Systems (LIMS), Neuroinformatics Software, Telemedicine Software 5) By Services: Diagnostic Testing Services, Consultation Services, Training and Support Services, Maintenance and Repair Services for Equipment, Telehealth Services, Data Analysis Services, Research and Development Services

What Is The Driver Of The Neurological Disorder Diagnostics Market?

The increasing prevalence of Alzheimer's disease is expected to propel the growth of the neurological disorder diagnostics market going forward. Alzheimer's disease refers to a progressive neurodegenerative disorder characterized by a gradual decline in cognitive functions, including memory, reasoning, and problem-solving. Alzheimer's disease combines genetic factors, such as specific gene mutations and variations, the accumulation of amyloid plaques and tau tangles in the brain, chronic inflammation, vascular issues, and lifestyle factors. Neurological disorder diagnostics help Alzheimer's disease by enabling early and accurate detection through advanced imaging techniques, biomarker analysis, and cognitive assessments. For instance, in September 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, approximately 411,100 individuals in Australia were living with dementia, including around 257,500 women and 153,700 men. Thus, the increasing prevalence of Alzheimer's disease is driving the growth of the neurological disorder diagnostics industry.

Key Players In The Global Neurological Disorder Diagnostics Market

Major companies operating in the neurological disorder diagnostics market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Amgen Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Otsuka Pharmaceutical Co. Ltd., Boston Scientific Corporation, Neurocrine Biosciences Inc., Neusoft Medical Systems Co.Ltd., Nihon Kohden Corporation, Natus Medical Incorporated, Esaote S.p.A, Canon Medical Systems Corporation, NeuroPace Inc., Lifelines Neuro Company LLC, York Instruments Ltd., Advanced Brain Monitoring Inc., Neurometrix Inc., Croton Healthcare Private Limited, NeuroLogica Corporation

Global Neurological Disorder Diagnostics Market Trends and Insights

Major companies operating in the neurological disorder diagnostics market are focused on developing innovative solutions, such as neurological disease quantification software, for one billion individuals affected by neurological diseases worldwide. Neurological disease quantification software is a tool used to measure and analyze brain function and disease progression in neurological conditions. For instance, in January 2024, Quibim, a Spain-based biotechnology company, launched the QP-Brain, an AI-based early-stage neurological disease quantification software. QP-Brain by Quibim is advanced neuroimaging analysis software designed to quantify brain tissue alterations in neurological diseases. Its unique features include AI-powered automated segmentation and detailed volumetric analysis, offering precise insights into brain structure changes for clinical and research applications.

What Are Latest Mergers And Acquisitions In The Neurological Disorder Diagnostics Market?

In February 2023, Lantheus, a US-based pharmaceutical manufacturing company, acquired Cerveau Technologies for an undisclosed amount. Lantheus' acquisition of Cerveau and its tau-targeting PET imaging agent MK-6240 significantly enhances the ability to diagnose, stage, and monitor Alzheimer's disease while supporting the development of new treatments. Cerveau Technologies is a US-based company specializing in developing diagnostic technologies for neurological disorders, mainly focusing on neurodegenerative diseases such as Alzheimer's.

Regional Outlook

North America was the largest region in the neurological disorder diagnostics market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neurological Disorder Diagnostics Market?

The neurological disorder diagnostics market consists of revenues earned by entities by providing services such as neuroimaging, electrophysiological testing, genetic analysis, cerebrospinal fluid examination, neuropsychological assessments, and laboratory tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurological disorder diagnostics market also includes sales of imaging devices, biomarker tests, and cognitive assessment tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neurological Disorder Diagnostics Market Report 2026?

The neurological disorder diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neurological disorder diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.